Rosetta Genomics, Isis to Co-develop microRNA-based Drugs for Liver Cancer | GenomeWeb

NEW YORK, Feb. 22 (GenomeWeb News) - Isis Pharmaceuticals and Rosetta Genomics plan to co-discover and -develop antisense drugs that regulate microRNAs for the treatment of hepatocellular carcinoma, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.